ES2608317T3 - Derivados de 7-Azaindol - Google Patents

Derivados de 7-Azaindol Download PDF

Info

Publication number
ES2608317T3
ES2608317T3 ES12701437.1T ES12701437T ES2608317T3 ES 2608317 T3 ES2608317 T3 ES 2608317T3 ES 12701437 T ES12701437 T ES 12701437T ES 2608317 T3 ES2608317 T3 ES 2608317T3
Authority
ES
Spain
Prior art keywords
pyrrolo
atoms
salts
compounds
stereoisomers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12701437.1T
Other languages
English (en)
Spanish (es)
Inventor
Dieter Dorsch
Christian Sirrenberg
Thomas J.J. MUELLER
Eugen Merkul
Gnuni Amatunu KARAPETYAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2608317T3 publication Critical patent/ES2608317T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES12701437.1T 2011-02-01 2012-01-09 Derivados de 7-Azaindol Active ES2608317T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011009961 2011-02-01
DE102011009961A DE102011009961A1 (de) 2011-02-01 2011-02-01 7-Azaindolderivate
PCT/EP2012/000067 WO2012104007A2 (de) 2011-02-01 2012-01-09 7-azaindolderivate

Publications (1)

Publication Number Publication Date
ES2608317T3 true ES2608317T3 (es) 2017-04-07

Family

ID=45554609

Family Applications (3)

Application Number Title Priority Date Filing Date
ES12701437.1T Active ES2608317T3 (es) 2011-02-01 2012-01-09 Derivados de 7-Azaindol
ES16002047T Active ES2861048T3 (es) 2011-02-01 2012-01-09 Derivados de 7-azaindol
ES14000623.0T Active ES2634643T3 (es) 2011-02-01 2012-01-09 Derivados de 7-azaindol

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES16002047T Active ES2861048T3 (es) 2011-02-01 2012-01-09 Derivados de 7-azaindol
ES14000623.0T Active ES2634643T3 (es) 2011-02-01 2012-01-09 Derivados de 7-azaindol

Country Status (18)

Country Link
US (3) US8981101B2 (enExample)
EP (3) EP2746281B1 (enExample)
JP (1) JP5891249B2 (enExample)
KR (1) KR20140014158A (enExample)
CN (3) CN105712991B (enExample)
AR (1) AR085110A1 (enExample)
AU (1) AU2012213775B2 (enExample)
BR (1) BR112013019028A2 (enExample)
CA (2) CA3082435A1 (enExample)
DE (1) DE102011009961A1 (enExample)
EA (1) EA201300873A1 (enExample)
ES (3) ES2608317T3 (enExample)
HK (1) HK1226394A1 (enExample)
IL (1) IL227689A0 (enExample)
MX (1) MX2013008212A (enExample)
SG (1) SG192133A1 (enExample)
WO (1) WO2012104007A2 (enExample)
ZA (1) ZA201306542B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20130376A1 (es) * 2010-06-28 2013-03-30 Merck Patent Gmbh [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer
DE102010053347A1 (de) * 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
DE102011009961A1 (de) * 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
EP2817313B1 (en) * 2012-02-21 2016-09-07 Merck Patent GmbH Furopyridine derivatives
DE102012019369A1 (de) 2012-10-02 2014-04-03 Merck Patent Gmbh 7-Azaindolderivat
FR3001219A1 (fr) * 2013-01-22 2014-07-25 Centre Nat Rech Scient Inhibiteurs de kinases
GB201303109D0 (en) 2013-02-21 2013-04-10 Domainex Ltd Novel pyrimidine compounds
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
RU2680100C9 (ru) 2013-03-15 2019-04-18 Плексксикон Инк. Гетероциклические соединения и их применения
TW201613916A (en) 2014-06-03 2016-04-16 Gilead Sciences Inc TANK-binding kinase inhibitor compounds
CN106715419A (zh) 2014-09-26 2017-05-24 吉利德科学公司 用作tank‑结合激酶抑制剂化合物的氨基三嗪衍生物
EP3265072A1 (en) * 2015-03-04 2018-01-10 Dana-Farber Cancer Institute, Inc. Salicylate inhibitors of melk and methods of use
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
RU2018102685A (ru) * 2015-06-29 2019-08-02 Мерк Патент Гмбх СОЕДИНЕНИЯ-ИНГИБИТОРЫ TBK/IKKε И ИХ ПРИМЕНЕНИЕ
AU2016370916A1 (en) 2015-12-17 2018-06-07 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
WO2017102091A1 (en) 2015-12-18 2017-06-22 Bayer Pharma Aktiengesellschaft Heteroarylbenzimidazole compounds
CN105906608B (zh) * 2016-05-03 2018-10-19 中山大学 8-氨基喹啉-松果体素杂联体及其药物组合物
WO2017207534A1 (en) 2016-06-03 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted heteroarylbenzimidazole compounds
GB201702947D0 (en) 2017-02-23 2017-04-12 Domainex Ltd Novel compounds
JP7131837B2 (ja) * 2017-06-19 2022-09-06 アビスコ セラピューティクス カンパニー リミテッド Ｃｓｆ－１ｒ阻害活性を有するアザアリール誘導体、その製造方法および応用
US10717735B2 (en) 2017-10-13 2020-07-21 Plexxikon Inc. Solid forms of a compound for modulating kinases
US12448374B2 (en) 2018-06-07 2025-10-21 Disarm Therapeutics, Inc. Inhibitors of SARM1
ES3028093T3 (en) 2018-06-07 2025-06-18 Disarm Therapeutics Inc Inhibitors of sarm1
KR20200046680A (ko) * 2018-10-25 2020-05-07 한국과학기술원 Pdk1 저해제를 포함하는 역노화 유도용 조성물
WO2025016273A1 (zh) * 2023-07-14 2025-01-23 拜西欧斯（北京）生物技术有限公司 异喹啉衍生物、包含其的药物组合物以及它们的用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
JP2003500397A (ja) 1999-05-19 2003-01-07 スミスクライン ビーチャム パブリック リミテッド カンパニー Ｍｒｓ阻害剤としての２−ｎｈ−ピリドンおよびピリミドン
JP5095216B2 (ja) 2003-11-14 2012-12-12 ローラス セラピューティクス インコーポレーテッド アリールイミダゾールおよびその抗癌剤としての使用
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
WO2005095400A1 (en) 2004-03-30 2005-10-13 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of jak and other protein kinases
UA87494C2 (en) * 2004-03-30 2009-07-27 Вертекс Фармасьютикалс Инкорпорейтед Azaindoles useful as inhibitors of jak and other protein kinases
FR2868422B1 (fr) * 2004-03-31 2006-07-14 Aventis Pharma Sa Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US20080153869A1 (en) * 2004-06-14 2008-06-26 Bressi Jerome C Kinase Inhibitors
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
US7511056B2 (en) 2004-11-10 2009-03-31 Eli Lilly And Company TGF-β inhibitors
EP1828180A4 (en) 2004-12-08 2010-09-15 Glaxosmithkline Llc 1H-pyrrolo [2,3-BETA] PYRIDINE
AU2006232620A1 (en) 2005-04-06 2006-10-12 Astrazeneca Ab Substituted heterocycles and their use as CHK1, PDK1 and PAK inhibitors
US7541367B2 (en) 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
JP2007099640A (ja) * 2005-09-30 2007-04-19 Tsumura & Co 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物
CN101374839A (zh) * 2006-01-17 2009-02-25 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
NZ601687A (en) * 2006-01-17 2014-03-28 Vertex Pharma Azaindoles useful as inhibitors of janus kinases
DE102006012617A1 (de) 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
CA2659582A1 (en) 2006-06-22 2007-12-27 Merck & Co., Inc. Tyrosine kinase inhibitors
JP5642963B2 (ja) 2006-06-30 2014-12-17 スネシス ファーマシューティカルズ，インコーポレイティド ピリジノニルｐｄｋ１阻害剤
JP2010514693A (ja) 2006-12-22 2010-05-06 ノバルティス アーゲー Ｐｄｋ１阻害のためのキナゾリン
CA2679694A1 (en) 2007-03-13 2008-09-18 Merck & Co., Inc. Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1
US8367706B2 (en) 2007-06-20 2013-02-05 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
DE102007028515A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
WO2009054941A1 (en) 2007-10-25 2009-04-30 Merck & Co., Inc. Therapeutic compounds
CN101939324B (zh) 2008-02-25 2014-10-15 霍夫曼-拉罗奇有限公司 吡咯并吡嗪激酶抑制剂
DE102008025751A1 (de) * 2008-05-29 2009-12-03 Merck Patent Gmbh 4-(1H-Pyrrolo[2,3-b]pyridin-3-yl)-pyridin-2-ylamin-derivate
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
CN101723936B (zh) * 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
DE102009019962A1 (de) 2009-05-05 2010-11-11 Merck Patent Gmbh 3-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyridinderivate
NZ603644A (en) * 2010-05-24 2014-10-31 Univ Rochester Bicyclic heteroaryl kinase inhibitors and methods of use
PE20130376A1 (es) * 2010-06-28 2013-03-30 Merck Patent Gmbh [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer
DE102010053347A1 (de) 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
DE102011009961A1 (de) * 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate

Also Published As

Publication number Publication date
CN105732617A (zh) 2016-07-06
ZA201306542B (en) 2014-05-28
CN105712991B (zh) 2017-12-01
AU2012213775A1 (en) 2013-09-19
CA2826051A1 (en) 2012-08-09
BR112013019028A2 (pt) 2016-10-04
EP3133074A2 (de) 2017-02-22
CN105712991A (zh) 2016-06-29
EP2670748B1 (de) 2016-09-28
HK1226394A1 (zh) 2017-09-29
MX2013008212A (es) 2013-08-26
CA2826051C (en) 2020-08-18
CN105732617B (zh) 2017-12-01
WO2012104007A3 (de) 2013-10-17
CN103502247B (zh) 2016-02-24
US20130310391A1 (en) 2013-11-21
ES2634643T3 (es) 2017-09-28
AR085110A1 (es) 2013-09-11
CA3082435A1 (en) 2012-08-09
EP3133074B1 (de) 2020-12-09
DE102011009961A1 (de) 2012-08-02
EP2746281B1 (de) 2017-04-26
ES2861048T3 (es) 2021-10-05
US9266887B2 (en) 2016-02-23
CN103502247A (zh) 2014-01-08
EP2746281A2 (de) 2014-06-25
EP2670748A2 (de) 2013-12-11
AU2012213775A8 (en) 2013-10-24
IL227689A0 (en) 2013-11-25
US20150152104A1 (en) 2015-06-04
JP5891249B2 (ja) 2016-03-22
US8981101B2 (en) 2015-03-17
JP2014509313A (ja) 2014-04-17
US9725446B2 (en) 2017-08-08
US20160130269A1 (en) 2016-05-12
EP2746281A3 (de) 2014-10-08
AU2012213775B2 (en) 2016-11-10
WO2012104007A2 (de) 2012-08-09
SG192133A1 (en) 2013-08-30
EP3133074A3 (de) 2017-05-17
EA201300873A1 (ru) 2014-02-28
KR20140014158A (ko) 2014-02-05

Similar Documents

Publication Publication Date Title
ES2608317T3 (es) Derivados de 7-Azaindol
ES2436445T3 (es) Derivados de 3-([1,2,3]triazol-4-il)-pirrolo[2,3-b]piridina
JP5411849B2 (ja) ６−（ピロロピリジニル）−ピリミジン−２−イルアミン誘導体ならびに癌およびａｉｄｓの処置のためのその使用
ES2535607T3 (es) Derivados de 7-([1,2,3]triazol-4-il)-pirrolo[2,3-B]pirazina
ES2543563T3 (es) Derivados de 5-([1,2,3]triazol-4-il)-7H-pirrolo[2,3-D]pirimidina
JP5718359B2 (ja) ピロロ［２，３−ｂ］ピラジン−７−イルピリミジン化合物
JP2013544264A (ja) ＰＤＫ１阻害剤としての３−ヘタリール置換ピロロ［２，３−ｂ］ピリジン誘導体
CN103764651B (zh) 适合治疗癌症疾病的7-氮杂吲哚衍生物
HK1226407A1 (en) 7-azaindole derivatives
HK1189220A (en) 7-azaindole derivatives
HK1142332A (en) 6-(pyrrolopyridinyl)pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and aids